 CAMBRIDGE, Mass. , June 2, 2022 PRNewswire -- Nuvalent, Inc. Nasdaq: NUVL, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D. 